Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$2.17 +1.4%	$2.47	$1.28 ▼ $7.85	$235.16M	1.3	1.09 million shs	1.06 million shs
SYRE Spyre Therapeutics	$16.78 +2.6%	$16.16	$10.91 ▼ $40.26	$987.56M	2.82	516,968 shs	688,310 shs
UPB Upstream Bio	$17.74 +8.4%	$13.22	$5.14 ▼ $29.46	$881.96M	N/A	525,557 shs	421,874 shs
ZYME Zymeworks	$14.39 +0.5%	$13.17	$9.03 ▼ $17.70	$1.08B	1.26	530,490 shs	315,163 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-2.28%	-17.69%	-13.36%	+3.88%	-64.27%
SYRE Spyre Therapeutics	+1.49%	-6.03%	0.00%	+8.49%	-38.74%
UPB Upstream Bio	-3.20%	-11.85%	+53.76%	+75.73%	+1,635,999,900.00%
ZYME Zymeworks	+1.56%	+2.73%	0.00%	+24.74%	+31.74%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANNX Annexon	2.9004 of 5 stars	3.4	3.0	3.7	2.5	0.0
SYRE Spyre Therapeutics	2.8645 of 5 stars	3.6	2.0	2.6	2.5	0.6
UPB Upstream Bio	2.125 of 5 stars	3.5	0.0	2.4	0.8	0.6
ZYME Zymeworks	1.8387 of 5 stars	3.5	0.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.75	Moderate Buy	$12.50	476.04% Upside
SYRE Spyre Therapeutics	3.29	Buy	$53.40	218.24% Upside
UPB Upstream Bio	3.00	Buy	$56.50	218.49% Upside
ZYME Zymeworks	2.90	Moderate Buy	$21.43	48.91% Upside

Current Analyst Ratings Breakdown

Latest ANNX, ZYME, SYRE, and UPB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/11/2025	ZYME Zymeworks	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $22.00
8/6/2025	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$65.00
7/3/2025	ZYME Zymeworks	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$13.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
SYRE Spyre Therapeutics	$890K	1,138.78	N/A	N/A	$4.97 per share	3.38
UPB Upstream Bio	$2.37M	403.53	N/A	N/A	$7.58 per share	2.34
ZYME Zymeworks	$122.87M	8.80	N/A	N/A	$6.63 per share	2.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-70.04%	-57.67%	N/A
SYRE Spyre Therapeutics	-$208.02M	-$3.40	N/A	N/A	N/A	N/A	-71.30%	-38.69%	11/6/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	-3,836.58%	-35.90%	-26.26%	11/6/2025 (Estimated)
ZYME Zymeworks	-$118.67M	-$0.97	N/A	N/A	N/A	-182.75%	-23.00%	-18.04%	10/30/2025 (Estimated)

Latest ANNX, ZYME, SYRE, and UPB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/7/2025	N/A	ZYME Zymeworks	-$0.52	$0.03	+$0.55	N/A	$17.18 million	$48.73 million
8/6/2025	Q2 2025	UPB Upstream Bio	-$0.61	-$0.74	-$0.13	-$0.74	$0.32 million	$0.94 million
8/5/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.73	-$0.49	+$0.24	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A
ZYME Zymeworks	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.67	7.99
SYRE Spyre Therapeutics	N/A	6.49	6.49
UPB Upstream Bio	N/A	38.27	38.27
ZYME Zymeworks	N/A	4.10	4.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
SYRE Spyre Therapeutics	80.39%
UPB Upstream Bio	N/A
ZYME Zymeworks	92.89%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	11.87%
SYRE Spyre Therapeutics	15.43%
UPB Upstream Bio	13.56%
ZYME Zymeworks	1.92%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	109.89 million	96.84 million	Optionable
SYRE Spyre Therapeutics	73	60.40 million	51.08 million	Optionable
UPB Upstream Bio	38	53.91 million	46.60 million	N/A
ZYME Zymeworks	460	75.17 million	67.56 million	Optionable

ANNX, ZYME, SYRE, and UPB Headlines

Recent News About These Companies

Zymeworks Reports Q2 Results and FDA Clearance

August 19 at 9:47 AM | theglobeandmail.com

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19 at 6:00 AM | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Shares Purchased by Tejara Capital Ltd

August 17, 2025 | marketbeat.com

Zymeworks Earnings Call: Revenue Surge and Strategic Gains

August 13, 2025 | msn.com

Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

August 12, 2025 | zacks.com

Citigroup Raises Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | marketbeat.com

Citigroup Increases Zymeworks (NYSE:ZYME) Price Target to $22.00

August 12, 2025 | americanbankingnews.com

Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

August 12, 2025 | marketbeat.com

Zymeworks Inc.: Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | finanznachrichten.de

Zymeworks Strengthens Leadership with New Board Appointments

August 11, 2025 | tipranks.com

Zymeworks Inc. Appoints Greg Ciongoli and Robert E. Landry to Board of Directors

August 11, 2025 | quiverquant.comQ

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | financialpost.comF

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025 | globenewswire.com

Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from Analysts

August 11, 2025 | marketbeat.com

Earnings Beat: Zymeworks Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

August 10, 2025 | finance.yahoo.com

Zymeworks (NYSE:ZYME) Announces Earnings Results, Beats Expectations By $0.55 EPS

August 9, 2025 | marketbeat.com

Zymeworks signals expanded royalty streams and milestone-driven cash infusions through new approvals and pipeline progression

August 8, 2025 | msn.com

Zymeworks Inc. (ZYME) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates

August 7, 2025 | zacks.com

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Zymeworks (ZYME) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX, ZYME, SYRE, and UPB Company Descriptions

Annexon NASDAQ:ANNX

$2.17 +0.03 (+1.40%)

Closing price 04:00 PM Eastern

Extended Trading

$2.16 0.00 (-0.23%)

As of 07:58 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Spyre Therapeutics NASDAQ:SYRE

$16.78 +0.43 (+2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$17.15 +0.37 (+2.21%)

As of 07:58 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Upstream Bio NASDAQ:UPB

$17.74 +1.38 (+8.44%)

Closing price 04:00 PM Eastern

Extended Trading

$17.75 +0.01 (+0.06%)

As of 05:13 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Zymeworks NYSE:ZYME

$14.39 +0.07 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$14.30 -0.09 (-0.63%)

As of 05:12 PM Eastern

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time